Yizhou Dong, PhD
Dr. Dong’s research, cell-specific and multifunctional drug delivery in vivo, has been regarded as one of the most challenging issues in the field of drug delivery. A wide variety of cell types in humans still cannot be efficiently and specifically reached by delivery systems such as lung epithelial cells, metastatic tumor cells, and immune cells. An even more formidable task is delivering multiple payloads into specific cells and tissues. In order to address these challenges, Dr. Dong’s Drug Discovery and Delivery Laboratory focuses on the following research areas, developing cell specific drug delivery systems, constructing multifunctional drug delivery systems and demonstrating therapeutic efficacy of these systems in animal models for treating genetic disorders, infectious diseases and cancers.
Platform biotechnologies under development in the Drug Discovery and Delivery Laboratory include:
- Developing new biomaterials for therapeutic and diagnostic applications
- Engineering RNA molecules including mRNAs and the CRISPR systems
- Constructing targeted drug conjugates such as antibody/ligand drug conjugates.
Dan Shu, PhD
Dr. Shu has devoted her research career to the development of RNA nanotechnology for the treatment of cancers, specifically focusing on the treatment of breast cancer, including triple negative breast cancer. Dr. Shu is developing novel therapeutics utilizing RNA nanoparticles for the specific delivery of small interfering miRNA or siRNA to cancers and related stem cells. Her long-term objective is to focus on the development and translation of RNA nanotechnology-based therapeutics and imaging agents into clinical trials.